Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1431-1440 Newer>

Managed Care September 2004 Sherrie Dulworth	CAM Offerings Really Can Enhance Quality of Care for Some Patients People flock to complementary and alternative medicine (CAM) services whether insurers cover them or not. When does it make economic and medical sense to offer them?
Managed Care September 2004 Tony Berberabe	Can Physician and Health Plan Get Together Over Guidelines? Physicians are not the only problem. Health plans too often view guidelines as rigid routines rather than flexible aids to good practice.
Managed Care September 2004 John A. Marcille	Can Health Care Institutions Exploit Today's Opportunity? The increasing concern by businesses over the current inflation in health care costs is an opportunity, but is our inertia so pervasive that we cannot respond with the kind of controls that will bring health care inflation into balance with the rest of the economy?
Managed Care September 2004 John Carroll	Pfizer: DM Did Not Fizzle In Florida Medicaid Ruckus Medicaid officials close the books on a program the pharmaceutical giant contends that soon-to-be-released data will verify its disease management program's effectiveness.
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
BusinessWeek October 11, 2004 Gene G. Marcial	Clear Vistas at Advanced Medical Optics This manufacturer of eye surgery products isn't a household name, but its stock hit a 52-week high of 43 in late June, up from 17 in November. And a recent slide is no sign of a downturn, says one investment analyst.
BusinessWeek October 11, 2004 Gene G. Marcial	Can Axonyx Help Treat Alzheimer's? With a number of products in its pipeline and $93 million in cash, the company "heads my list in biotechs," says the top biotech analyst at Rodman & Renshaw. Its Phenserine, which is already in Phase 3 trials, may be a valuable weapon in combatting Alzheimer's.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool September 30, 2004 Charly Travers	Biomira Drug's on the Fast Track Investors rally on the good news, but what does fast-track status really mean?
The Motley Fool September 29, 2004 Charly Travers	Nabi Stamps Out Smoking A nicotine vaccine looks to help smokers kick the habit.
<Older 1431-1440 Newer> Return to current articles.